bismuth-tripotassium-dicitrate and Chronic-Disease

Topics: Bismuth; Campylobacter Infections; Chronic Disease; Dose-Response Relationship, Drug; Gastritis; Humans; Organometallic Compounds; Salicylates

To evaluate the efficacy and safety of modified sequential therapy and to compare modified sequential therapy with standard quadruple therapy for Helicobacter pylori (H. pylori) eradication.. In total, 200 consecutive patients who were diagnosed with H. pylori-infected chronic gastritis by electronic endoscopy and rapid urease testing from December 2012 to October 2013 were enrolled in this study. The patients had not previously received H. pylori eradication treatment, and were randomized into two groups. The patients in Group A (n = 101) were treated with ilaprazole + bismuth potassium citrate + amoxicillin and clavulanate potassium + levofloxacin, and the patients in Group B (n = 99) were administered a modified sequential therapy composed of ilaprazole at 5 mg bid and amoxicillin and clavulanate potassium at 914 mg for the first five days followed by ilaprazole at 5 mg bid, furazolidone at 100 mg bid and levofloxacin at 500 mg qid for the next five days. Four to six weeks after the end of treatment, a 14C-urea breath test was performed for all the subjects to confirm the eradication of H. pylori. The intention-to-treat and per-protocol eradication rates were determined.. A total of 190 of the 200 patients completed the study. All 200 patients were included in the intention-to-treat analysis, whereas 190 patients were included in the per-protocol analysis. In the intention-to-treat analysis, the rates of H. pylori eradication in Groups A and B were 85.15% (86/101) and 81.82% (81/99), respectively. In the per-protocol analysis, the H. pylori eradication rates in Groups A and B were 88.66% (86/97) and 87.09% (81/93), respectively. No significant difference was observed (χ(2) = 0.109, P = 0.741) in the eradication rate between Groups A and B. The rates of adverse effects observed in the groups were similar at 6.19% (6/97) for Group A and 7.53% (7/93) for Group B (P > 0.05). No mortality or major morbidities were observed in any of the patients. Symptomatic improvements in the presentation of stomachache, acid regurgitation, and burning sensation were not significantly different between the two groups.. Ilaprazole-based 10-d standard quadruple therapy does not offer an incremental benefit over modified sequential therapy for the treatment of H. pylori infection, as both treatment regimens appear to be effective, safe, and well-tolerated as initial treatment options.

Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; China; Chronic Disease; Clavulanic Acid; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Time Factors; Treatment Outcome

To elucidate the influences of H pylori infection on oral iron treatment for iron deficiency anemia (IDA).. A total of 86 patients were divided into two groups: group A, receiving ferrous succinate combined with triple therapy for H pylori eradication, and group B (control), treated with ferrous succinate only. During treatment of IDA, dynamic changes in hemoglobin (Hb) level, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), serum iron (SI), and serum ferritin (SF) were compared between the groups.. Hb was slightly higher in group A at d 14 after the start of triple therapy for H pylori eradication (P > 0.05). After the therapy, the increase of Hb in group A became significantly faster than that in group B (P < 0.05). At d 56, the mean Hb in group A returned to the normal level, however, in group B, it was lower than that in group A (P < 0.05) although it had also increased compared with that before oral iron treatment. The MCV and MCH in group A recovered to the normal level, and were much higher than those in group B (P < 0.05) at d 21. In Group B, the MCV and MCH remained at lower than normal levels until d 42 after the start of therapy. And then, they reached a plateau in both groups and the differences disappeared (P > 0.05). The SF in group A was higher than that in group B (P < 0.05) 28 d after the treatment and its improvement was quicker in group A (P < 0.05) , and the difference between the two groups was even more significant (P < 0.01) at d 56. The SI in group A was higher than that in group B (P < 0.05) at d 14 and this persisted until d 56 when the follow-up of this research was finished.. Treatment of H pylori can enhance the efficacy of ferrous succinate therapy in IDA patients with H pylori-positive chronic gastritis.

Topics: Adolescent; Adult; Aged; Amoxicillin; Anemia, Iron-Deficiency; Anti-Infective Agents; Chronic Disease; Drug Therapy, Combination; Erythrocyte Indices; Female; Ferritins; Ferrous Compounds; Gastritis; Helicobacter Infections; Helicobacter pylori; Hemoglobins; Humans; Iron; Male; Metronidazole; Middle Aged; Organometallic Compounds; Risk Factors

Clinical and instrumental-laboratory investigations have been conducted in 372 patients with chronic antral gastritis (CAG, n = 131), diffuse gastritis (DG, n = 108) and ulcer disease (UD, n = 135). Immunomodulators tactivin and levamisol were added to standard treatment of 75 CAG, 63 DG and 85 UD patients. Healing of the lesions was observed, on the average, on the treatment day 24.3 +/- 0.5 and 18.4 +/- 0.6 in the standard treatment and with the added immunomodulator, respectively. Adjuvant levamisol diminished the number of recurrences of chronic gastritis and UD.

Topics: Adjuvants, Immunologic; Anti-Infective Agents; Chronic Disease; Drug Administration Schedule; Drug Therapy, Combination; Duodenoscopy; Gastritis; Gastroscopy; Humans; Levamisole; Organometallic Compounds; Peptides; Stomach Ulcer; Thymus Extracts

Both iron deficiency anaemia and Helicobacter pylori infection are rare in developed countries. A possible connection has been suggested between these two diseases and our aim was to define the clinical picture and to study the effect of bacterial eradication in H. pylori colonized children with severe anaemia.. Eight children with iron deficiency anaemia refractory to iron supplementation were examined with gastroscopy because of suspicion of H. pylori infection. Anaemia was treated with oral ferrous sulphate. Two patients needed blood transfusions. Eradication therapy was given either with combination of colloidal bismuth subcitrate and metronidazole or with omeprazole, clarithromycin and amoxycillin. Eradication was confirmed by urea breath test 4 weeks post-treatment.. H. pylori infection was confirmed histologically and microbiologically in all children, who also presented with chronic, active gastritis. Bacteria were successfully eradicated in 7/8 patients. Correction of haemoglobin values was observed post-treatment, iron stores still being deficient at control in 4/8 children.. Our results suggest that H. pylori might have a role in causing iron deficiency anaemia in school-age children. Screening for H. pylori should be extended to cover those patients with other clinical manifestations than symptoms from gastrointestinal tract.

Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Hemoglobins; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Urea

In a randomized, endoscopically controlled trial, the effects of colloidal bismuth subcitrate (CBS) tablets on the healing of chronic duodenal ulcers were compared with those of ranitidine (R). 38 patients were originally allocated to the CBS group and 37 to ranitidine. There were 5 dropouts in each group. Of 33 patients given CBS, 25 (75%) showed complete ulcer healing by 4 weeks and 30 (91%) by 8 weeks. Of the 32 patients given ranitidine, 28 (87%) showed complete ulcer healing by 4 weeks and 30 (94%) by 8 weeks. There was no significant difference between these results. Symptom resolution was similar in both groups and no significant adverse effects were noted.

Topics: Adult; Aged; Anti-Ulcer Agents; Bismuth; Chronic Disease; Clinical Trials as Topic; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Organometallic Compounds; Random Allocation; Ranitidine

Thirty-seven patients with chronic duodenal ulceration were entered into an endoscopically controlled trial of cimetidine (Tagamet) versus tri-potassium di-citrato bismuthate (De-Nol). At six weeks, 83% of patients taking cimetidine showed complete ulcer healing compared with 74% of patients taking tri-potassium di-citrato bismuthate. By ten weeks, the corresponding figures were 89% and 84% respectively. Symptomatic relief was similar in both treatment groups and, despite advice to the contrary, continued smoking and alcohol consumption did not appear to adversely affect healing. Both drugs appear to be equally effective in healing chronic duodenal ulcers.

Topics: Adult; Aged; Alcohol Drinking; Anti-Ulcer Agents; Bismuth; Chronic Disease; Cimetidine; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulcer; Female; Guanidines; Humans; Male; Middle Aged; Organometallic Compounds; Smoking

Sixty patients with benign chronic gastric ulcer were treated in a controlled clinical trial to assess the relative efficacy of cimetidine and tri-potassium di-citrato bismuthate (De-Nol). Patients were assigned at random either to cimetidine or to De-Nol treatment after initial endoscopic diagnosis. Healing was assessed endoscopically after six weeks by an endoscopist who had no knowledge of the patients' treatment. Consumption of analgesic preparations (both for medical and for non-medical reasons), of other anti-inflammatory agents, and of alcohol and cigarettes was recorded. Of the 57 patients who were reassessed at six weeks, 30 had been assigned to De-Nol and 20 of these patients (66%) had completely healed; 27 patients had been assigned to cimetidine and 17 of these (63%) had also completely healed. Those patients who regularly ingested more than four analgesic preparations a day healed less frequently, but this effect was not statistically significant. There was no significant difference between cimetidine and De-Nol in the initial healing of chronic gastric ulceration. The choice of therapy for chronic gastric ulceration will depend on cost, patient acceptance, and data from studies of more complex therapeutic regimens.

Topics: Analgesics; Anti-Inflammatory Agents; Bismuth; Chronic Disease; Cimetidine; Citrates; Female; Gastroscopy; Guanidines; Humans; Male; Organometallic Compounds; Prospective Studies; Random Allocation; Stomach Ulcer

Microcirculatory disturbances in chronic gastric erosions (CGE) were evaluated in 95 chronic gastric (CGE) patients using Doppler laser flowmetry to examine terminal blood flow of the gastric mucosa. Microcirculatory impairment in the fundal area was found in 93.7% patients with CGE, in the antral one in all the examinees. Patients with multiple and recurrent erosions and erosions associated with Helicobacter pylori had most pronounced microcirculatory disorders, especially in the antral stomach. When chronic erosions were treated with triad therapy on the basis of De-nol, the percentage of eradication exceeded 80%. The addition to therapy of the immunomodulator galavit promotes more effective and adequate restoration of blood flow in CGE patients.

Topics: Adjuvants, Immunologic; Anti-Ulcer Agents; Chronic Disease; Female; Gastric Mucosa; Humans; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Organometallic Compounds; Peptic Ulcer; Pyloric Antrum; Regional Blood Flow

Topics: Abdominal Pain; Adolescent; Adult; Age Factors; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Child; Chronic Disease; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Penicillins; Recurrence; Risk Factors; Stomach Ulcer

Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Chronic Disease; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer; Peptic Ulcer Hemorrhage; Recurrence

Thirty-nine Helicobacter pylori (HP) positive chronic duodenal ulcer patients completed the 4 weeks treatment of triple therapy (Denol, Metronidazole and Amoxil). Of these 29 showed healed duodenal ulcer and negative CLO test at 8 weeks (eradication). They were followed at 3,6 and 12 months and at each follow-up, endoscopy and CLO testing were repeated. At 12 weeks, 54% showed a healed ulcer and negative CLO and these figures reached to 69 and 66% at 6 and 12 months respectively. Thirty percent relapsed within 1 year. The present study indicates a prolonged remission of duodenal ulcer following HP eradication.

Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Pakistan; Treatment Outcome; Wound Healing

The eradication of Helicobacter pylori is becoming the therapy of choice for peptic ulcers, if the infection is present. Published data from primary care settings are, however, limited.. An open-ended, prospective study was undertaken that included 31 patients with active peptic ulcer demonstrated by endoscopy and H pylori infection confirmed by urease and histologic tests. After a 14-day period of treatment with omeprazole, bismuth, tetracycline, and metronidazole, healing and H pylori status were evaluated by repeat endoscopy done at least 28 days after the last treatment dose. Eradication is defined as absence of H pylori in at least four (two from the fundus and two from the antrum) samples taken from the gastric mucosa and a negative urease test. Drug side effects and patient compliance were monitored in all cases.. Twenty-eight patients completed the protocol. Healing was obtained in all cases, and eradication was accomplished in 25 (89%). Side effects were common (69%) but mild. Compliance was good. After a mean follow-up of 300 days (range, 180 to 400), one ulcer recurrence was observed in an H pylori-positive patient and none in H pylori-negative patients.. The treatment of H pylori infection is an effective way of healing peptic ulcers, and can be applied in primary care settings. Further studies with more patients and with shorter and easier therapies should be undertaken to confirm our findings.

Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Drug Therapy, Combination; Endoscopy; Evaluation Studies as Topic; Family Practice; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Tetracycline; Treatment Outcome

This study tested the influence of pretreatment bacterial density on the eradication rate of Helicobacter pylori with triple therapy. One hundred and thirty two patients with endoscopically confirmed H pylori positive, duodenal ulcer or antral gastritis were treated with triple therapy (colloidal bismuth/metronidazole/amoxicillin) for two weeks. Pretreatment urease activity was assessed by the 14C-urea breath test (UBT) in all patients. The mean (SD) pretreatment UBT concentration was similar in patients with duodenal ulcers (318.4 (175.0)) and patients with antral gastritis (288.9 (165.5)). Overall eradication of H pylori was achieved in 85 of 132 patients (64.4%), but was significantly different between patients with high, intermediate, or low pretreatment urease activity (37.5%, 69.5%, and 87.8% respectively). The mean post-treatment UBT value of patients in whom eradication failed was in direct correlation with the pretreatment UBT values. In conclusion, bacterial density, as assessed by urease activity, is an important factor in predicting H pylori eradication. It is suggested that the pretreatment UBT has the potential to identify patients who require modification of the standard therapeutic regimen.

Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Chronic Disease; Colony Count, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Urea; Urease

Helicobacter pylori causes chronic (type B) gastritis. The 'intestinal' form of gastric cancer arises against a background of chronic gastritis, and prospective epidemiological studies have shown that H pylori is a major risk factor for this. An increase in mucosal cell proliferation increases the likelihood of a neoplastic clone of epithelial cells emerging where there is chronic epithelial cell injury associated with H pylori gastritis. In vitro bromodeoxyuridine labelling of endoscopic antral biopsy specimens was used to measure mucosal cell proliferation in H pylori associated gastritis before and after therapy for H pylori triple infection. Cell proliferation was increased in H pylori associated gastritis patients compared with normal controls and patients with H pylori negative chronic gastritis (p = 0.0001; Tukey's Studentised range). There was no difference in antral epithelial cell proliferation between duodenal ulcer and non-ulcer subjects infected with H pylori (p = 0.62; Student's t test). Antral mucosal cell proliferation fell four weeks after completing triple therapy, irrespective of whether or not H pylori had been eradicated (p = 0.0001). At retesting six to 18 months later (mean = 12 months), however, those in whom H pylori had not been successfully eradicated showed increased mucosal proliferation compared with both H pylori negative subjects at a similar follow up interval and all cases (whether H pylori positive or negative) four weeks after completion of triple therapy (p = 0.024). These findings suggest that H pylori infection causes increased gastric cell proliferation and in this way may play a part in gastric carcinogenesis.

Topics: Adult; Cell Division; Chronic Disease; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Immunohistochemistry; Metronidazole; Organometallic Compounds; Tetracycline

Topics: Amoxicillin; Anemia, Hypochromic; Anti-Bacterial Agents; Antibodies, Bacterial; Child; Chronic Disease; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Male; Organometallic Compounds; Pyloric Antrum

The present study evaluated the effect of a one-day high-dose combined therapy on Helicobacter pylori infection. Thirty-two consecutive patients (suffering from either peptic ulcer or nonulcer dyspepsia) with Helicobacter pylori infection received omeprazole (40 mg) + bismuth subcitrate (240 mg x 4) + amoxicillin suspension (2000 mg x 4) + metronidazole (500 mg x 4), for only one day. Endoscopy, histology, culture, and susceptibility studies were done at entry and 30 and 90 days after the treatment day. Successful eradication was obtained in 23/32 (72%) patients and gastritis had resolved in 95% of these. Side effects were induced by the treatment in 6/32 (19%) patients, but these were all self-limiting, short-lasting, and did not require any specific treatment. Development of bacterial resistance to metronidazole occurred in 6/9 (67%) non-eradicated patients. These data suggest that one-day treatment with high doses of amoxicillin, metronidazole, bismuth, and omeprazole represents an effective, safe, and inexpensive therapeutic approach for the treatment of H. pylori infection.

Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Treatment Outcome

Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Drug Therapy, Combination; Duodenitis; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer; Recurrence

A 15-year-old girl was admitted after 1 week of increasing fatigue and pallor. She had no gastro-intestinal complaints. The patient had suffered from four episodes of syncope during the last 3 days prior to admission. Besides pallor and a discrete cardiac murmur, the physical examination was normal. A further thorough investigation revealed an iron deficiency anaemia related to a Helicobacter pylori positive chronic active haemorrhagic gastritis. Treatment consisted of amoxycillin and colloidal bismuth subcitrate (500 mg and 120 mg orally respectively, 3 times daily) during a period of 6 weeks. Iron supplements were not administered. Together with the clearance of H. pylori and healing of the haemorrhagic gastritis, as demonstrated by histology, haemoglobin values returned to normal and the symptoms disappeared. An eradication of the micro-organism was obtained. She has since had no further similar complaints.

Topics: Adolescent; Amoxicillin; Anemia, Hypochromic; Anti-Ulcer Agents; Biopsy; Chronic Disease; Female; Gastric Mucosa; Gastritis; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Syncope

Altogether 89 patients with long non-healing gastric ulcers were examined for Campylobacter pylori (CP) and mucous microflora. It is shown that in patients with long non-healing gastric ulcers, CP was only demonstrable in 19.8% of cases whereas pathological microflora (Candida and microbial associations) in 72.3% of cases. In patients with CP, the administration of de-nol, metronidazole and ampicillin were not sufficiently effective.

Topics: Adult; Ampicillin; Anti-Ulcer Agents; Campylobacter; Chronic Disease; Female; Gastric Mucosa; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Stomach Ulcer; Wound Healing

The authors investigated the effect of one month bismuth treatment (Bismuthi citrici 120 mg per capsule), 4 x 120 mg/day, on morphological changes of the gastric mucosa along with the effect on Campylobacter pylori (CP) in a group of 23 probands with histologically verified active superficial CP positive antrum gastritis. The probands suffered only from functional dyspepsia, to eliminate the action of other disease of the digestive tract on chronic gastritis. Complete eradication of CP occurred in 65.2% and disappearance of granulocytic infiltration as a manifestation of activity in 73.9%. The disappearance of activity correlated with the eradication of CP in 88.2. The authors evaluated also the degree of circular nuclear cellulization (grade 1-3). After one-month treatment it was reduced by 1 grade in 56.5% in the antrum, while in the corpus it remained unaltered in the majority. Complete histological normalization of the mucosa was not recorded.

Topics: Adult; Antacids; Chronic Disease; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Organometallic Compounds

Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Campylobacter; Campylobacter Infections; Chronic Disease; Duodenal Ulcer; Gastritis; Humans; Organometallic Compounds; Pyloric Antrum; Recurrence; Risk Factors

Topics: Adult; Anti-Ulcer Agents; Campylobacter Infections; Chronic Disease; Female; Gastritis; Humans; Male; Organometallic Compounds

Topics: Campylobacter Infections; Chronic Disease; Humans; Organometallic Compounds; Peptic Ulcer

Topics: Acute Disease; Antacids; Antibodies, Bacterial; Campylobacter; Campylobacter Infections; Chronic Disease; Gastritis; Humans; Organometallic Compounds; Prospective Studies

Colloidal bismuth subcitrate (CBS) precipitates in an acid environment, adheres to mucus, blocks pepsin activity, retards hydrogen-ion back diffusion and stimulates prostaglandin synthesis. The average healing rate after 4 weeks' treatment with CBS is 78% in duodenal ulcer versus 67% with cimetidine. A direct comparison with ranitidine gives healing rates of 78% (CBS) as opposed to 78% with ranitidine. The corresponding figures in gastric ulcer are 68% (CBS) and 54% (cimetidine). The percentage of relapse-free patients is substantially higher after CBS ulcer healing than after H2-blockers. Bismuth subsalicylate eliminates Campylobacter pylori in 71% after 4-weeks' therapy. Parallel to this elimination a decrease and normalization of the acute inflammatory process can be seen in antral mucosa.

Topics: Anti-Ulcer Agents; Bismuth; Campylobacter Infections; Chronic Disease; Duodenal Ulcer; Gastritis; Humans; Organometallic Compounds; Peptic Ulcer; Salicylates; Stomach Ulcer

In 1983, bacteriological examinations of gastric epithelium isolated a new species of bacteria, the so-called Campylobacter pyloridis. These bacteria were found in 50% of the gastroscopic examinations from patients with dyseptic disorders. C. pyloridis is a gram-negative curved bacterium. Up to now it has been found on the surface of the human gastric epithelium. C. pyloridis is rarely isolated from the healthy gastric epithelium. The gastric epithelium containing C. pyloridis mostly suffers from inflammatory infiltration or from pathological changes like chronic gastritis of type B. The route of infection is unknown. C. pyloridis has not yet been isolated outside of the human stomach. For laboratory diagnosis of a disease caused by C. pyloridis, the bacterium has to be isolated from gastric bioptic specimen. Another possibility is to check for high serum antibody levels against C. pyloridis. Direct microscopic examinations of gastric epithelium are also possible. The positive urease test is the main criterion to differentiate C. pyloridis from other human pathogenic campylobacter species. As therapeutic agents are recommended: bismuthates, amoxicillin, furazolidone and tinidazole. These agents are able to eliminate C. pyloridis from gastric epithelium and to fade away the gastritis.

Topics: Amoxicillin; Antibodies, Bacterial; Biopsy; Bismuth; Campylobacter; Campylobacter Infections; Chronic Disease; Furazolidone; Gastric Mucosa; Gastritis; Humans; Organometallic Compounds; Tinidazole; Urease

A patient with chronic erosive gastritis and protein-losing gastropathy is reported. Presentation was with weight loss and abdominal discomfort. There were endoscopic and radiological features of erosive gastritis. Radioactive chromium studies confirmed that the low serum albumin was associated with fecal protein loss. No improvement occurred with bed rest or Caved S but coincided with DeNol therapy.

Topics: Aged; Bismuth; Chronic Disease; Female; Gastritis; Glycyrrhiza; Humans; Organometallic Compounds; Plants, Medicinal; Protein-Losing Enteropathies; Smallpox